Journals LibraryNHS NIHR - National Institute for Health Research
HTA - 16/51/19
Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer [ID56]
Project title: Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer [ID56]
Call to action: 16/51 CDF Transition Topics - Groups 1,3&6
Research type: Evidence Synthesis
Contractor: University of Sheffield
Started: September 2016 | Status: Published March 2019
PROSPERO registration: CRD42016050403
Cabozantinib and vandetanib improved progression-free survival; however, significant overall survival benefits were not demonstrated and the incremental cost-effectiveness ratio was > £138,000 per QALY gained.
Links to project documentation
The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.